UPDATE: Response Genetics' Q4 Revenues Slide 23 Percent as Project Nears End | GenomeWeb

This article has been updated to clarify the status of Response Genetics' alliance with GlaxoSmithKline, which is ongoing.

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Response Genetics today reported a 23 percent year-over-year drop in revenues for its fourth quarter, driven by a decrease in pharmaceutical client revenue.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genome sequencing study of Yakutian horses, tardigrade genome, and more.

A guest post at Retraction Watch discusses what funders can do to improve research reproducibility.

Researchers report in Nature this week that farming led to genomic adaptations in humans.

The FDA argues that it needs to evaluate the safety and efficacy of laboratory-developed tests, a proposal that divides Republicans.